NEW YORK, August 22, 2021 / PRNewswire / –
WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of the securities of CorMedix Inc. (NASDAQ: CRMD) between July 8, 2020 and May 13, 2021, inclusive (the “Recourse Period”), September 20, 2021 lead applicant time limit.
SO WHAT: If you purchased any securities of CorMedix during the Class Period, you may be entitled to compensation without payment of any costs or additional charges through a contingency fee agreement.
WHAT TO DO NEXT: To join the CorMedix class action lawsuit, go to https://www.rosenlegal.com/cases-register-2126.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing [email protected] or [email protected] for information on the class action. A class action has already been filed. If you want to serve as the principal applicant, you must move the court not later than September 20, 2021. A principal plaintiff is a representative party acting on behalf of the other members of the class to direct the litigation.
WHY THE ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, companies providing reviews do not have comparable experience, resources or peer recognition. Be wise in choosing the right lawyer. Rosen law firm represents investors around the world, focusing its practice on class actions in securities and derivative litigation between shareholders. Rosen law firm has secured the largest securities class action settlement against a Chinese company. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds millions of dollars for investors. In 2019 alone, the company achieved more than $ 438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as Titan of the Plaintiff’s Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, the defendants throughout the litigation period made false and / or misleading statements and / or failed to disclose that: (1) deficiencies existed with respect to the manufacturing process of DefenCath , a purported new antibacterial and antifungal solution designed to prevent and prevent dangerous blood infections associated with catheters (“CRBSI”), and / or the facility responsible for manufacturing DefenCath; (2) in light of the above shortcomings, it was unlikely that the United States Food and Drug Administration (“FDA”) would approve the DefenCath New Drug Application (“NDA”) for CRBSI in its current form; (3) the defendants had downplayed the actual extent of the deficiencies in the manufacturing process of DefenCath and / or the facility responsible for manufacturing DefenCath; and (4) accordingly, the defendants’ public statements were materially false and misleading at all material times. When the real details entered the market, the lawsuit claims that investors have suffered damage.
To join the CorMedix class action lawsuit, go to https://www.rosenlegal.com/cases-register-2126.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing [email protected] or [email protected] for information on the class action.
No class has been certified. Until a group is certified, you are not represented by a lawyer unless you hire one. You can choose the lawyer of your choice. You can also remain an absent group member and do nothing at this point. The ability of an investor to participate in any potential future recovery does not depend on whether he or she is a lead applicant.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Lawyer advertising. Previous results do not guarantee a similar result.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Rosen Law Firm, Pennsylvania
275 Madison Avenue, 40th Floor
New York, New York State 10016
Phone. : (212) 686-1060
Toll free: (866) 767-3653
Fax: (212) 202-3827
View original content to download multimedia: https://www.prnewswire.com/news-releases/rosen-top-ranked-investor-counsel-encourages-cormedix-inc-investors-with-losses-in-excess-of -100k -to-secure-a-advice-before-the-important-deadline-of-September-20-in-the-classic-recourse-in-titles – crmd-301360213.html
SOURCE Rosen Law Firm, Pennsylvania